Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Waverley PharmaTSXV:WAVE +50.00% Market Cap is C$0.81 Mil as of Jul. 26, 2026. The stock has 5 warning signs investors should review. Among 1,423 Biotechnology companies, Waverley Pharma ranks worse than 99.16% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Waverley Pharma's share price for the quarter that ended in Mar. 2026 was C$0.015. Waverley Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 54.00 Mil. Therefore, Waverley Pharma's market cap for the quarter that ended in Mar. 2026 was C$0.81 Mil.
Waverley Pharma's quarterly market cap
stayed the same
from Sep. 2025 (C$1.08 Mil) to Dec. 2025 (C$1.08 Mil) but then
declined
from Dec. 2025 (C$1.08 Mil) to Mar. 2026 (C$0.81 Mil).
Waverley Pharma's annual market cap
declined
from Dec. 2023 (C$1.35 Mil) to Dec. 2024 (C$0.54 Mil) but then
increased
from Dec. 2024 (C$0.54 Mil) to Dec. 2025 (C$1.08 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Waverley Pharma's Enterprise Value for Today is C$4.28 Mil.
Waverley Pharma (TSXV:WAVE) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Waverley Pharma Market Cap Related Terms
Waverley Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Waverley Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:WAVE vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Waverley Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Waverley Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Waverley Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Waverley Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Waverley Pharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Waverley Pharma (TSXV:WAVE) has a Market Cap of C$0.81 Mil as of Jul. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Waverley Pharma and its competitors. According to the industry distribution chart, Waverley Pharma ranks #1411 out of 1423 companies in the Biotechnology industry, placing it in the top 99.2%.
Is Waverley Pharma's Market Cap too high?
Waverley Pharma's current Market Cap is C$0.81 Mil. Based on the distribution chart, Waverley Pharma ranks #1411 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Waverley Pharma's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Waverley Pharma ranks #1411 out of 1423 companies for Market Cap. This places Waverley Pharma in the lower half of its industry. The industry median Market Cap is 112.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.84, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Waverley Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Waverley Pharma's current Market Cap is C$0.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Waverley Pharma stock overvalued right now?
Based on GuruFocus' analysis, Waverley Pharma (TSXV:WAVE) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.07, compared to a current price of C$0.02 — trading 78.6% below its estimated fair value. The current Market Cap is C$0.81 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Waverley Pharma (TSXV:WAVE), the current Market Cap is C$0.81 Mil as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics focused on oncology. The company's product pipeline includes Bortezomib, Pemetrexed, Capecitabine, and Temozolomide, among others. The company operates in one business segment, the biopharmaceutical industry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:WAVE has been successfully added to your 
